Oral treatment with laquinimod augments regulatory T-cells and brain-derived neurotrophic factor expression and reduces injury in the CNS of mice with experimental autoimmune encephalomyelitis

Journal of Neuroimmunology

Volumn 251, Issue 1-2, 2012, Pages 14-24

  Aharoni, Rina ^a   Saada, Ravit ^a   Eilam, Raya ^a   Hayardeny, Liat ^b   Sela, Michael ^a   Arnon, Ruth ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b Pharmacology Unit   (Israel)

Author keywords

Brain derived neurotrophic factor (BDNF); Experimental autoimmune encephalomyelitis (EAE); Laquinimod; Multiple sclerosis; Neuroprotection; T regulatory cells

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; LAQUINIMOD;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTOSIS; AXONAL INJURY; CONTROLLED STUDY; DEMYELINATION; DRUG MECHANISM; FEMALE; IMMUNOMODULATION; MOUSE; MULTIPLE SCLEROSIS; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE;

ANIMALS; AXONS; BRAIN-DERIVED NEUROTROPHIC FACTOR; DEMYELINATING DISEASES; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; IMMUNOLOGIC FACTORS; MICE; MICE, INBRED C57BL; MULTIPLE SCLEROSIS; NEUROPROTECTIVE AGENTS; QUINOLONES; T-LYMPHOCYTES, REGULATORY;

EID: 84865631399     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2012.06.005     Document Type: Article

References (26)

1. Aharoni R., Arnon R. Linkage between immunomodulation neuroprotection and neurogenesis. Drug News Perspect. 2009, 22:301-313.
2. Aharoni R., Eylam R., Domev H., Labunsky G., Sela M., Arnon R. The immunomodulator glatiramer acetate augments the expression of neurotrophic factors in brains of experimental autoimmune encephalomyelitis mice. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:19045-19050.
3. Aharoni R., Arnon R., Eilam R. Neurogenesis and neuroprotection induced by peripheral immunomodulatory treatment of experimental autoimmune encephalomyelitis. J. Neurosci. 2005, 25:8217-8228.
4. Azoulay D., Vachapova V., Shihman B., Miler A., Karni A. Lower brain-derived neurotrophic factor in serum of relapsing remitting MS: reversal by glatiramer acetate. J. Neuroimmunol. 2005, 167:215-218.
5. Behi M.E., Dubucquoi S., Lefranc D., Zephir H., De Seze J., Vermersch P., Prin L. New insights into cell responses involved in experimental autoimmune encephalomyelitis and multiple sclerosis. Immunol. Lett. 2005, 96:11-26.
6. Bjartmar C., Wujek J.R., Trapp B.D. Axonal loss in the pathology of MS: consequences for understanding the progressive phase of the disease. J. Neurol. Sci. 2003, 15:165-171.
7. Bruck W. Evidence for primary neurodegeneration in MS. Mult. Scler. 2008, (Supp1):9-13.
8. Brück W., Wegner C. Insight into the mechanism of laquinimod action. J. Neurol. Sci. 2011, 306:173-179.
9. Brunmark C., Runström A., Ohlsson L., Sparre B., Brodin T., Aström M., Hedlund G. The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis. J. Neuroimmunol. 2002, 130:163-172.
10. Comi G., Pulizzi A., Rovaris M., Abramsky O., Arbizu T., Boiko A., Gold R., Havrdova E., Komoly S., Selmaj K., Sharrack B., Filippi M., LAQ/5062 Study Group Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 2008, 371:2085-2092.
11. Comi G., Jeffery D., Kappos L., Montalban X., Boyko A., Rocca M.A., Filippi M., ALLEGRO Study Group Placebo-controlled trial of oral laquinimod for multiple sclerosis. N. Engl. J. Med. 2012, 366:1000-1009.
12. Feng G., Mellor R.H., Bernstein M., Keller-Peck C., Nguyen Q.T., Wallace M., Nerbonne J.M., Lichtman J.W., Sanes J.R. Imaging neuronal subsets intransgenic mice expressing multiple spectral variants of gfp. Neuron 2000, 28:41-51.
13. Gurevich M., Gritzman T., Orbach R., Tuller T., Feldman A., Achiron A. Laquinimod suppresses antigen presentation in relapsing-remitting multiple sclerosis: in-vitro high-throughput gene expression study. J. Neuroimmunol. 2010, 221:87-94.
14. Hellings N., Raus J., Stinissen P. Insights into the immunopathogenesis of multiple sclerosis. Immunol. Res. 2002, 25:27-51.
15. Hohlfeld R., Wekerle H. Autoimmune concepts of MS as a basis for selective immunotherapy: from the pipe dreams to therapeutic pipelines. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:14599-14606.
16. Kalb R. The protean actions of neurotrophins and their receptors on the life and death of neurons. Trends Neurosci. 2005, 28:5-11.
17. Lassmann H., Bruck W., Lucchinetti F. The immunopathology of MS: an overview. Brain Pathol. 2007, 17:210-218.
18. Linker R.A., Lee D.H., Demir S., Wiese S., Kruse N., Siglienti I., Gerhardt E., Neumann H., Sendtner M., Lühder F., Gold R. Functional role of brain-derived neurotrophic factor in neuroprotective autoimmunity: therapeutic implications in a model of multiple sclerosis. Brain 2010, 133:2248-2263.
19. Murer M.G., Yan O., Raisman-Vozari R. Brain-derived neurotrophic factor in the control human brain, and in Alzheimer's disease and Parkinson's disease. Prog. Neurobiol. 2001, 63:7-124.
20. Riley C.P., Cope T.C., Buck C.R. CNS neurotrophins are biologically active and expressed by multiple cell types. J. Mol. Histol. 2004, 35:771-783.
21. Stadelmann C., Kerschensteiner M., Misgeld T., Bruck W., Hohlfeld R., Lassmann H. BDNF and gp145 trkB in multiple sclerosis brain lesions: neuroprotective interactions between immune and neuronal cells. Brain 2002, 125:75-85.
22. Thöne J., Ellrichmann G., Seubert S., Peruga I., Lee D.H., Conrad R., Hayardeny L., Comi G., Wiese S., Linker R.A., Gold R. Modulation of autoimmune demyelination by laquinimod via induction of brain-derived neurotrophic factor. Am. J. Pathol. 2012, 180:267-274.
23. Trap B.D., Nave K.A. Multiple sclerosis an immune or neurodegenerative disease. Annu. Rev. Neurosci. 2008, 31:247-269.
24. Vila J., Isaacs J.D., Anderson A.E. Regulatory T cells and autoimmunity. Curr. Opin. Hematol. 2009, 16:274-279.
25. Wegner C., Stadelmann C., Pförtner R., Raymond E., Feigelson S., Alon R., Timan B., Hayardeny L., Brück W. Laquinimod interferes with migratory capacity of T cells and reduces IL-17 levels, inflammatory demyelination and acute axonal damage in mice with experimental autoimmune encephalomyelitis. J. Neuroimmunol. 2010, 227:133-143.
26. Yang J.S., Xu L.Y., Xiao B.G., Hedlund G., Link H. Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-beta in Lewis rats. J. Neuroimmunol. 2004, 56:3-9.